UM: Phase III Trial Evaluating Arimoclomol for ALS Patients Reaches Full Enrollment

UM: Phase III Trial Evaluating Arimoclomol for ALS Patients Reaches Full Enrollment

An international phase III clinical trial evaluating the drug Arimoclomol for the treatment of amyotrophic lateral sclerosis (ALS) has reached full enrollment, as reported by a University of Miami Miller School of Medicine researcher. The current phase III trial builds upon the results of a prior phase II trial that enrolled patients with a rapidly progressive, rare genetic form of ALS.

Full Story

Related posts

Scripps: Mutated coronavirus shows significant boost in infectivity

A tiny genetic mutation in the SARS coronavirus 2 variant circulating throughout Europe and the…

FAU: Could These ‘Salt-loving’ Edible Sea Vegetables be the New Kale?

Researchers from Florida Atlantic University’s Harbor Branch Oceanographic Institute recently completed a 10-week study to…

USF ranks among academic world leaders in U.S. patent production

With 108 new U.S. utility patents granted in 2019, USF is eighth among American public…